By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


SEARCH JOBS

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at http://www.alkermes.com.

Key Executives
Richard F. Pops
Chairman and Chief Executive Officer

Shane Cooke
President

Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer

Mark Stejbach
Senior Vice President, Chief Commercial Officer

Georgianna Harris
Vice President, Regulatory Affairs

Madeline D. Coffin
Vice President, Human Resources

Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer

James M. Frates
Senior Vice President, Chief Financial Officer

Blair C. Jackson
Vice President, Business Development

Michael J. Landine
Senior Vice President, Corporate Development

Rebecca J. Peterson
Senior Vice President, Corporate Communications

Gordon G. Pugh
Senior Vice President, Chief Operating Officer and Chief Risk Officer

Peter Norman
Vice President, Government Affairs and Policy

Srdjan Stankovic
Senior Vice President, Clinical Development and Medical Affairs

Locations

Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642


Key Statistics


Email: mediainfo@alkermes.com
Ownership: Public

Web Site: Alkermes plc
Employees: 1,200
Symbol: ALKS
 




Segment
Drug Delivery





Company News
Alkermes plc (ALKS) Reports Second Quarter 2014 Financial Results 7/31/2014 10:38:27 AM
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014 9:25:43 AM
Alkermes plc (ALKS) To Host Conference Call To Discuss Second Quarter 2014 Financial Results 7/25/2014 9:14:38 AM
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 7/17/2014 10:25:54 AM
Alkermes plc (ALKS) Announces Notices of Allowance For U.S. Patents For Four CNS Pipeline Candidates 7/9/2014 11:18:27 AM
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/18/2014 7:21:16 AM
Alkermes plc (ALKS) Announces Initiation Of FORWARD-3 And FORWARD-4 Efficacy Studies In Pivotal Program For ALKS 5461 For Treatment Of Major Depressive Disorder 6/10/2014 9:50:03 AM
Alkermes plc (ALKS) Files Trademark Infringement Suit Against Boston-Based Biotech Startup Alkeus Pharmaceuticals 6/6/2014 6:57:21 AM
Alkermes plc (ALKS) To Present Data On New Medicines In Development For Schizophrenia And Depression At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 6/3/2014 6:57:19 AM
Alkermes plc (ALKS) Announces Initiation Of Second Phase 2 Clinical Study Of ALKS 3831, A Novel Broad-Spectrum Oral Antipsychotic 6/2/2014 9:04:40 AM
12345678910...
//-->